These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 17346612)

  • 21. Gatekeeping strategies for clinical trials that do not require all primary effects to be significant.
    Dmitrienko A; Offen WW; Westfall PH
    Stat Med; 2003 Aug; 22(15):2387-400. PubMed ID: 12872297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo.
    Pigeot I; Schäfer J; Röhmel J; Hauschke D
    Stat Med; 2003 Mar; 22(6):883-99. PubMed ID: 12627407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Practical usage of O'Brien's OLS and GLS statistics in clinical trials.
    Dallow NS; Leonov SL; Roger JH
    Pharm Stat; 2008; 7(1):53-68. PubMed ID: 17390306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A two stage conditional power adaptive design adjusting for treatment by covariate interaction.
    Ayanlowo AO; Redden DT
    Contemp Clin Trials; 2008 May; 29(3):428-38. PubMed ID: 18053774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction of group sequential designs in clinical trials on the basis of detectable treatment differences.
    Schäfer H; Müller HH
    Stat Med; 2004 May; 23(9):1413-24. PubMed ID: 15116350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adaptive designs based on the truncated product method.
    Neuhäuser M; Bretz F
    BMC Med Res Methodol; 2005 Sep; 5():30. PubMed ID: 16171518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gatekeeping procedures with clinical trial applications.
    Dmitrienko A; Tamhane AC
    Pharm Stat; 2007; 6(3):171-80. PubMed ID: 17583553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal designs for estimating the interesting part of a dose-effect curve.
    Miller F; Guilbaud O; Dette H
    J Biopharm Stat; 2007; 17(6):1097-115. PubMed ID: 18027219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Power and sample size.
    Case LD; Ambrosius WT
    Methods Mol Biol; 2007; 404():377-408. PubMed ID: 18450060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bayesian sample size calculations for a non-inferiority test of two proportions in clinical trials.
    Daimon T
    Contemp Clin Trials; 2008 Jul; 29(4):507-16. PubMed ID: 18201944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methodological and statistical problems in uvulopalatopharyngoplasty research: a follow-up study.
    Megwalu UC; Piccirillo JF
    Arch Otolaryngol Head Neck Surg; 2008 Aug; 134(8):805-9. PubMed ID: 18711052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A practical limit to trials needed in one-person randomized controlled experiments.
    Alemi R; Alemi F
    Qual Manag Health Care; 2007; 16(2):130-4. PubMed ID: 17426611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining proof-of-concept with dose-finding: utilization of adaptive designs in migraine clinical trials.
    Sagkriotis A; Scholpp J
    Cephalalgia; 2008 Aug; 28(8):805-12. PubMed ID: 18513264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statistical power and sample size estimation for headache research: an overview and power calculation tools.
    Houle TT; Penzien DB; Houle CK
    Headache; 2005 May; 45(5):414-8. PubMed ID: 15953257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests.
    Polley MY; Cheung YK
    Biometrics; 2008 Mar; 64(1):232-41. PubMed ID: 17573866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis and importance of statistical power and sample size in empirical scientific research].
    Klimek KM
    Wiad Lek; 2008; 61(7-9):211-5. PubMed ID: 19172834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repeated confidence intervals for adaptive group sequential trials.
    Mehta CR; Bauer P; Posch M; Brannath W
    Stat Med; 2007 Dec; 26(30):5422-33. PubMed ID: 17918195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sample size calculation for the Power Model for dose proportionality studies.
    Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
    Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A two-stage phase II trial design utilizing both primary and secondary endpoints.
    Lin X; Allred R; Andrews G
    Pharm Stat; 2008; 7(2):88-92. PubMed ID: 17252536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Negative results and the limitations of power.
    Penington A
    ANZ J Surg; 2008; 78(1-2):99-102. PubMed ID: 18199219
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.